SCHEMBL6421066

SCHEMBL6421066

Oc1ccccc1C=NNc1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.54
KDM4E B2RXH2 9/20 0.54
MAPT P10636 8/20 0.54
MEN1 O00255 8/20 0.54
HTT P42858 7/20 0.54
TDP1 Q9NUW8 3/20 0.54
POLB P06746 2/20 0.54
BLM P54132 1/20 0.54
DDX3X O00571 3/20 0.52
SMN1; SMN2 Q16637 9/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 4/20 0.45
GAA P10253 3/20 0.45
ALDH1A1 P00352 3/20 0.45
GFER P55789 1/20 0.45
LMNA P02545 3/20 0.44
RECQL P46063 1/20 0.42
USP2 O75604 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RAB9A P51151 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432629 0.91 KMT2A (0.56) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6417232 0.87 DDX3X (0.49) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6419770 0.86 DDX3X (0.45) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL13310234 0.85 KMT2A (0.47) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6418421 0.85 SMN1; SMN2 (0.44) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6418385 0.85 KMT2A (0.47) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6439515 0.83 MAPT (0.51) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6436226 0.83 MAPT (0.51) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6431997 0.83 KMT2A (0.45) KMT2AKDM4EMAPTMEN1HTT
SCHEMBL6438165 0.83 GAA (0.45) KMT2AKDM4EMAPTMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 KMT2A 3640/4885KDM4E 3277/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.